Jun 07, 2022 6:30am EDT Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
Jun 06, 2022 6:30am EDT Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
May 31, 2022 8:30am EDT Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7
May 25, 2022 8:30am EDT Veru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022
May 18, 2022 8:30am EDT Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients
May 17, 2022 8:30am EDT Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022
May 12, 2022 6:30am EDT Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
May 11, 2022 6:30am EDT FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
May 02, 2022 8:30am EDT FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Apr 28, 2022 8:30am EDT Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th
